It is currently Tue Sep 30, 2014 3:39 am

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Oral MS drug piloted in North East is available on the NHS

Image

NHS funding for a groundbreaking drug piloted in the North East for patients with multiple sclerosis is now mandatory.

The National Institute for Clinical Excellence (Nice) has stipulated that adults with relapsing remitting MS not responding to treatment with first-line interferon injections should have access to fingolimod, an oral pill that cuts relapses by more than half compared to a standard injection.

Clinical trials that began in 2004 at the regional centre for the ...
Read more : Oral MS drug piloted in North East is available on the NHS | Views : 1215 | Replies : 0


MS drug Gilenya prescriptions slowing

MS drug Gilenya prescriptions slowing due to lack of monitoring facilities

Image


Novartis’ multiple sclerosis (MS) pill Gilenya faces slowing prescriptions in New York because of a lack of facilities to perform first-dose observations, neurologists told Biopharm Insight. However, Novartis has been in contact with a number of clinicians and is working on increasing the number of sites.

A US Food and Drug Administration (FDA) review was initiated after a patient died within 24 hours ...
Read more : MS drug Gilenya prescriptions slowing | Views : 1523 | Replies : 0


Oral MS drug Gilenya slows brain inflammation

Image

The multiple sclerosis medication fingolimod (Gilenya) led to "rapid and sustained" reductions in MRI-documented inflammatory lesion activity, researchers reported.

In a two-year randomized trial, the medication also slowed the rate of brain volume loss compared with placebo, according to Ernst-Wilhelm Radue, MD, of University Hospital Basel in Basel, Switzerland, and colleagues.

Changes in lesion volume over time also favoured the medication rather than placebo, Radue and colleagues reported online in Archives of Neurology.

Combined ...
Read more : Oral MS drug Gilenya slows brain inflammation | Views : 1337 | Replies : 0


Gilenya® shows long-term efficacy and safety - study

Gilenya® shows long-term efficacy and safety in extension of phase III head-to-head study

Image

New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment. These results, from an extension of the phase III head-to-head TRANSFORMS study, also showed improved efficacy for patients switched to Gilenya from ...
Read more : Gilenya® shows long-term efficacy and safety - study | Views : 1534 | Replies : 0


FDA issues new advice on oral MS drug Gilenya

Image


As their European counterparts did last month, the FDA has recommended continued use of the Gilenya multiple sclerosis pill sold by Novartis, but did say the drug should carry stronger warnings about heart risks and that some patients should undergo increased monitoring. The move was largely expected after the European Medicines Agency issued a similar alert, despite arguments by a non-profit safety watchdog that further restrictions are needed.

Although cardiovascular risks were known at ...
Read more : FDA issues new advice on oral MS drug Gilenya | Views : 1811 | Replies : 0


cost?

Hello all

sorry.. as i am sure this has been addressed before- but this is a new topic to me--what does everyone pay for gilenya--
seems to me here in Calgary it's about $2600. a month-- are there any subsidies available.?. how do people ( average people with average jobs afford this med?)

any info would be appreciated
thanks
Andie
Read more : cost? | Views : 1662 | Replies : 1


New MS oral drug, Gilenya, still not available in Eire

Image

A new oral drug to treat the symptoms of Multiple Sclerosis, which has been licensed and deemed cost-effective here, remains unavailable to sufferers.

The final stage in the HSE’s process before which it could be prescribed was “neither fair nor transparent”, a leading neurologist has said.

Prof Orla Hardiman, consultant neurologist at Beaumont Hospital in Dublin, said the MS drug Gilenya had been assessed and deemed cost-effective at the National Centre for Pharmacoeconomics (NCPE) ...
Read more : New MS oral drug, Gilenya, still not available in Eire | Views : 1582 | Replies : 0


first (and last) dose

I just took a dose of Gilenya in Los Angeles. Background: I was on ABCRs for seven years, dropped Avonex around New Year's due to a breakthrough relapse, went on Tysabri but had to leave because I had developed antibodies. After a frustrating two months without treatment, I finally got on Gilenya last night.

In the screening process, I learned that I have an unusually low heart rate (probably due to good overall cardio health ...
Read more : first (and last) dose | Views : 2212 | Replies : 0


EU supports oral MS drug, Gilenya, with stronger warning

Image

European regulators have endorsed the continued use of Novartis AG's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, but said on Friday the drug needed to carry stronger warnings on heart risks.

Novartis said the decision meant the drug remained on-track to be a "blockbuster" - one with annual sales above $1 billion.

Prospects for Gilenya, the first multiple sclerosis (MS) pill of its kind, have been clouded by ...
Read more : EU supports oral MS drug, Gilenya, with stronger warning | Views : 1422 | Replies : 0


7 year extension data for Gilenya

Extension study data for Gilenya® shows patients successfully treated for up to 7 years

Image

New data will be presented at the 64th annual meeting of the American Academy of Neurology (AAN) that support the efficacy and safety profile of Gilenya® (fingolimod), the only oral therapy approved to treat relapsing forms of multiple sclerosis (MS).

"The data being presented reinforce our confidence in the sustained efficacy and safety profile of Gilenya," said David Epstein, Head ...
Read more : 7 year extension data for Gilenya | Views : 1451 | Replies : 0


 

Login  •  Register


Statistics

Total posts 220270 • Total topics 22792 • Total members 14386


Contact us | Terms of Service